These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 21435191)

  • 1. A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP™) mostly excludes the presence of lupus anticoagulant.
    Mameli A; Barcellona D; Vannini ML; Marongiu F
    Int J Lab Hematol; 2011 Oct; 33(5):e12-3. PubMed ID: 21435191
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated partial thromboplastin time reagent sensitivity to the presence of the lupus anticoagulant.
    Adcock DM; Marlar RA
    Arch Pathol Lab Med; 1992 Aug; 116(8):837-40. PubMed ID: 1497465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for lupus anticoagulant: improving the performance of the lupus-sensitive PTT-LA.
    Luginbühl R; Barizzi G; Sulzer I; Lämmle B; Alberio L
    Int J Lab Hematol; 2011 Apr; 33(2):168-75. PubMed ID: 20860735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
    Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupus Anticoagulant Testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT).
    Tripodi A; Chantarangkul V
    Methods Mol Biol; 2017; 1646():177-183. PubMed ID: 28804829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
    Moore GW; Rangarajan S; Savidge GF
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants.
    Devreese KM
    Thromb Res; 2007; 120(3):427-38. PubMed ID: 17156825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lupus anticoagulant testing: effect of the platelet count on the activated partial thromboplastin time.
    Brien WF; Schaus MR; Cooper KE; O'Keefe BT; Inwood M
    Br J Biomed Sci; 1993 Jun; 50(2):114-6. PubMed ID: 8219916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant.
    Benattar N; Schved JF; Biron-Andréani C
    Thromb Haemost; 2000 Jun; 83(6):967-8. PubMed ID: 10896260
    [No Abstract]   [Full Text] [Related]  

  • 10. Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
    Robert A
    Thromb Haemost; 1994 Feb; 71(2):220-4. PubMed ID: 8191402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalence of prolonged APTT and lupus anticoagulant in autoimmune thyroid disease].
    Tani Y; Morita M; Noguchi S
    Rinsho Byori; 1997 Sep; 45(9):899-902. PubMed ID: 9311265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total knee replacement in a patient with lupus anticoagulant.
    Bhagia UT; Corpe RS; Steflik D
    J South Orthop Assoc; 1997; 6(3):231-4. PubMed ID: 9322205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis.
    Shimura H; Imai Y; Ieko M; Shiseki M; Mori N; Teramura M; Motoji T
    Ann Hematol; 2013 Jan; 92(1):143-4. PubMed ID: 22864763
    [No Abstract]   [Full Text] [Related]  

  • 14. Testing strategies for diagnosing lupus anticoagulant: decision analysis.
    Segal JB; Lehmann HP; Petri M; Mueller L; Kickler TS
    Am J Hematol; 2002 Jul; 70(3):195-205. PubMed ID: 12111765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient lupus anticoagulant and prolonged activated partial thromboplastin time secondary to Epstein-Barr virus infection.
    Shiomou K; Galanakis E; Tzoufi M; Tsaousi C; Papadopoulou ZL
    Scand J Infect Dis; 2002; 34(1):67-9. PubMed ID: 11874171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated partial thromboplastin time sensitivity to lupus anticoagulant in a patient with transient arthritis and lupus anticoagulant-hypoprothrombinemia syndrome.
    Mauge L; Passeron A; Alhenc-Gelas M; Pouchot J; Darnige L
    Ann Hematol; 2015 Apr; 94(4):713-5. PubMed ID: 25380995
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection and quantitative evaluation of lupus circulating anticoagulant activity.
    Rosner E; Pauzner R; Lusky A; Modan M; Many A
    Thromb Haemost; 1987 Apr; 57(2):144-7. PubMed ID: 3110995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interference from lupus anticoagulant on von Willebrand factor measurement in splenic marginal zone lymphoma: a case report.
    Vinholt PJ; Nybo M
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):454-7. PubMed ID: 25485787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of low levels of lupus anticoagulant antibodies.
    Villa P; Mira Y; Ferrando F; Vayá A; Aznar J
    Thromb Res; 2005; 116(5):447-9. PubMed ID: 15925399
    [No Abstract]   [Full Text] [Related]  

  • 20. Activated protein C resistance and lupus anticoagulant in pregnancy.
    Busowski JD; Jenkins AD; Hale EU; Busowski M; Dacus JV
    J Matern Fetal Med; 1999; 8(6):298-9. PubMed ID: 10582865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.